# Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

> **NCT07729098** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Dheeraj Gandhi** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Subdural Hematoma

## Interventions

- **DRUG:** Bevacizumab (intra-arterial)

## Key facts

- **NCT ID:** NCT07729098
- **Lead sponsor:** Dheeraj Gandhi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729098, "Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*